Invitrogen™ BAFF/IL-17A (Tibulizumab Biosimilar) Recombinant Human Monoclonal Antibody

Catalog No.	Quantity
PIMA542177	100 μg

Catalog No. PIMA542177 Supplier Invitrogen™ Supplier No. MA542177

Description

Human Recombinant Monoclonal Antibody

Endotoxin level <0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt. This product is a Humanized mouse antibody.

BAFF is a membrane bound cytokine expressed by B cell lineage cells. The soluble form of the cytokine binds to the receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. BAFF is a potent B cell activator, and important for the proliferation and differentiation of B cells. BAFF is also expressed by T lymphocytes and has been shown to promote T cell activation and survival. Isoforms representing alternatively spliced, and glycosylated variants have been identified. Interleukin-17A (IL-17A, CTLA-8) is a CD4+ T cell-derived cytokine that promotes inflammatory responses in cell lines and is elevated in rheumatoid arthritis, asthma, multiple sclerosis, psoriasis, and transplant rejection. IL-17A is a 32 kDa long, disulfide-linked homodimer consisting of 136 amino acids that is a member of a six-species family of proteins (IL-17A-17F) and signals through the IL-17 receptor (IL-17R/CDw217). High levels of IL-17A homodimer are produced by activated peripheral blood CD4+ T-cells, and IL-17A also enhances expression of the intracellular adhesion molecule-1 (ICAM-1) in human fibroblasts. In particular, human IL-17A also stimulates epithelial, endothelial, or fibroblastic cells to secrete IL-6, IL-8, G-CSF, and PGE2. In the presence of human IL-17A, fibroblasts can sustain the proliferation of CD34+ hematopoietic progenitors and induce maturation into neutrophils. Mouse, rat, and human IL-17A can induce IL-6 secretion in mouse stromal cells, indicating that all homologs can recognize the mouse receptor. IL-17A regulates the activities of NF-kappa B and mitogen-activated protein kinases, stimulates the expression of IL-6 and cyclooxygenase-2 (PTGS2/COX-2), and enhances the production of nitric oxide (NO).

Specifications

• Antigen: BAFF/IL-17A (Tibulizumab Biosimilar)
• Applications: ELISA
• Classification: Recombinant Monoclonal
• Concentration: 0.71 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with no preservative; pH 7.4
• Gene Alias: LY 3090106; LY3090106; LY-3090106
• Host Species: Human
• Immunogen: Human IL17A/TNFSF13B/CD2μ.
• Purification Method: Protein A/G
• Quantity: 100 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Target Species: Human
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG4 κ
• Target Molecule: Chemical

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov